This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.
Insights
Emerging Treatments in Schizophrenia Video
Christoph U. Correll, Anissa Abi-Dargham, and Oliver Howes
Published: February 17, 2022
Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.
Quick Links:
Advertisement
Emerging Approaches in Schizophrenia
Stay informed with expert videos from Dr. Phillip Harvey and Dr. Christoph Correll regarding new research in schizophrenia. Read articles about emerging therapies like xanomeline-trospium and iclepertin, that target new pathways and may shape the future of schizophrenia care.
Advertisement
Advertisement